The imposition of tariffs by the United States government has introduced significant uncertainties across various industries, including biotechnology. This white paper examines the potential ramifications of these tariffs on biotech manufacturing, funding, and the localization of clinical trials. Additionally, it evaluates whether there is a discernible trend toward conducting more clinical trials in Europe.
White Paper
The Potential Impact of U.S. Tariffs on the Biotech Sector: Manufacturing, Funding, and Clinical Trials
Download PDF
Related Resources
All Resources

post
Common CDMO Contract Pitfalls (and How to Avoid Them)
Read More

post
When to Outsource Manufacturing to a CDMO vs. Build In-House
Read More

case-study
How a Medical Writing Partnership Drives Regulatory Success
Read More

white-paper
The CMC Project Manager: A Strategic Function, Not an Administrative One
Read More
Let's move from science to success.
Let’s Talk
